Abstracts tagged "adherence"

Abstract Number: 0625 • ACR Convergence 2021
Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes
Shivani Garg¹, Betty Chewning¹, Shelby Gomez¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Up to 83% of SLE patients are nonadherent to hydroxychloroquine (HCQ) which can result in up to 8-fold higher risk of early death. Yet,…
Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Shivani Garg¹, Karen Hansen², Betty Chewning¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
Abstract Number: 096 • 2020 Pediatric Rheumatology Symposium
Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE
Rotem Semo Oz¹, Linda Wagner-Weiner ², Cuoghi Edens ¹, Grace Cameron ¹ and Melissa Tesher ¹, ¹university of chicago, Chicago, ²University of Chicago, Chicago, Illinois
Background/Purpose: Compared to adults with SLE, young patients with SLE face particular challenges, including more severe disease, more renal involvement and medications side effects like…
Abstract Number: 2238 • 2019 ACR/ARP Annual Meeting
Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment of rheumatoid arthritis (RA) to remission optimally ensures control of symptoms, prevention of structural damage, optimization of function and quality of life. Adherence…
Abstract Number: 2543 • 2019 ACR/ARP Annual Meeting
Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE
Shivani Garg¹, Rachna Unnithan ², Karen Hansen ³, Nathalie Costedoat-Chalumeau ⁴ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW- Madison, Madison, ³UW Madison, Madison, ⁴Cochin University Hospital, Paris, France
Background/Purpose: Despite the pivotal role hydroxychloroquine (HCQ) plays in treating SLE, less than 50% of patients take HCQ as prescribed. Nonadherence versus lack of effect…
Abstract Number: 2575 • 2019 ACR/ARP Annual Meeting
Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks
Onengiya Harry¹, Tracy Ting ² and Jennifer Huggins ², ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Young adults with childhood-onset lupus (cSLE) are 20 times more likely to die compared to healthy age- and gender-matched counterparts. Their clinical course is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].